Archives
-
Hepatic sEH, Nrf2, and Osteoporosis
2026-09-02
This study identifies a liver–bone signaling axis in which hepatic soluble epoxide hydrolase alters circulating 14,15-EET and 14,15-DHET, suppresses Nrf2-ARE activity, and promotes osteoclastogenesis. Its combination of patient samples, ovariectomy-induced osteoporosis, liver-specific knockdown, pharmacological inhibition, and transcriptomics provides a mechanistic framework for studying lipid redox regulation in bone disease.
-
Necrostatin 2: A Membrane-Aware Cell Death Strategy
2026-09-01
Necrostatin 2 (Nec-2) is a potent small-molecule tool for dissecting necroptosis inhibition and RIPK2 signaling. This article connects its use in ischemic stroke research with new membrane-level insights from ferroptosis biology, helping researchers design more discriminating cell-death assays.
-
Protease and Phosphatase Inhibitor Cocktail Guide
2026-09-01
Learn how Protease and Phosphatase Inhibitor Cocktail (EDTA Free, 100X in ddH2O), SKU K4006, helps preserve protein abundance and phosphorylation states during lysate-based analysis. This scenario-driven guide connects practical assay controls with macrophage HMGB1 research and provides evidence-based selection and workflow recommendations.
-
Foretinib Workflow for Cancer Assays
2026-08-31
Build more informative cancer drug-response studies with Foretinib (GSK1363089), from concentration-response testing to motility and metastasis-oriented models. The workflow separates growth arrest from cell killing so a reduced viability signal is interpreted rather than overgeneralized.
-
GDC-0941: A Causal Map for PI3K Assays
2026-08-31
GDC-0941 is a potent PI3K inhibitor for connecting target engagement with cancer cell proliferation inhibition, resistance biology, and pathway-state measurements. This article develops an assay-interpretation framework informed by recent pancreatic cancer research rather than repeating a conventional product or workflow overview.
-
ML365 and Postoperative Cognitive Impairment in Aged Mice
2026-08-30
A 2024 Brain Research study found that ML365 pretreatment reduced postoperative cognitive impairment in aged mice after exploratory laparotomy, alongside lower hippocampal NLRP3 inflammasome signaling and systemic oxidative stress. The work provides a pharmacological bridge between two-pore potassium-channel biology and postoperative neuroinflammation, while leaving direct TASK1 target engagement and clinical translation unresolved.
-
Guanabenz Acetate: Assay Design for α2 Signaling
2026-08-29
Guanabenz Acetate is a useful α2-adrenergic receptor agonist for subtype-resolved GPCR experiments. This article presents an assay-centered framework that separates receptor pharmacology from stress-granule and innate-immunity phenotypes.
-
Clathrin-Mediated Entry of Grass Carp Reovirus
2026-08-28
Wang et al. used pharmacological inhibitors, transmission electron microscopy, and real-time quantitative PCR to show that genotype III grass carp reovirus enters CIK cells through dynamin-dependent, pH-sensitive clathrin-mediated endocytosis. The study also found that Latrunculin B did not block productive entry under the tested conditions, illustrating how actin perturbation can serve as a pathway-discriminating control rather than a universal entry inhibitor.
-
A 83-01 ALK Inhibitor Workflow Guide
2026-08-28
Build cleaner TGF-β experiments with A 83-01, from dose–response reporter assays to organoid and EMT workflows. This guide connects selective pathway inhibition with the WNT-driven biliary proliferation model reported in JCI Insight while emphasizing controls, solubility, and interpretation limits.
-
RapaLink-1 for mTORC1 Inhibition and Dormancy
2026-08-27
RapaLink-1 is a third-generation mTOR inhibitor that combines bivalent target engagement with practical workflows for glioma assays, pathway validation, and diapause-like dormancy research. Its resistance-oriented design makes it useful when rapamycin or earlier kinase inhibitors produce incomplete pathway suppression.
-
GDC-0941: PI3K/Akt–Wnt Assay Strategy
2026-08-27
Explore how GDC-0941 can dissect PI3K/Akt signaling, treatment resistance, and phenotype switching. This article connects selective PI3K inhibition with practical assay decisions inspired by recent CDK4/6–BET research in pancreatic cancer.
-
Pexidartinib (PLX3397): From CSF1R to Translation
2026-08-26
Pexidartinib (PLX3397) offers a precise way to interrogate CSF1R-dependent myeloid biology. By connecting tumor-associated macrophage research with evidence on microglial control of hippocampal synapses, this article outlines validation strategies, experimental safeguards, and translational opportunities without overstating cross-domain evidence.
-
Amitriptyline HCl: Practical Assay Guide
2026-08-26
Amitriptyline HCl (SKU B2231) provides a characterized small-molecule reference for multi-receptor inhibition studies, solution preparation, and neuropharmacology research. It is suited to controlled in vitro workflows with prompt use of freshly prepared solutions, but should not be treated as a validated therapeutic model or used where long-term solution stability has not been established.
-
COX-2 in Venom-Induced Muscle Revascularization
2026-08-25
This study shows that COX-2 has a time-dependent role in skeletal muscle injury caused by Bothrops asper venom: its activity appears protective during acute ischemia but can restrain later angiogenic signaling. Using lumiracoxib in a mouse injury model, the authors connect COX-2 pathway modulation with prostaglandins, CD31, VEGF, and matrix metalloproteinases involved in microvascular repair.
-
GM 6001 (Galardin): From MMPs to Memory
2026-08-25
GM 6001 (Galardin) is a broad-spectrum MMP inhibitor that can help translational researchers test how extracellular matrix proteolysis shapes tissue repair, signaling, cancer phenotypes, vascular remodeling, and hippocampal perineuronal-net integrity. This article connects the compound’s pharmacology with recent Alzheimer’s disease findings while defining the controls needed to move from mechanistic observation to credible translational evidence.